{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS consisted of all enrolled participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 months","title":"Number of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure)","type":"PRIMARY","unitOfMeasure":"Participants"}